Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Short-term Investments: 2011-2022

Historic Short-term Investments for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Jun 2022 value amounting to $9.9 million.

  • Catalyst Pharmaceuticals' Short-term Investments fell 50.57% to $9.9 million in Q2 2022 from the same period last year, while for Jun 2022 it was $9.9 million, marking a year-over-year decrease of 50.57%. This contributed to the annual value of $19.8 million for FY2021, which is 97.40% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Short-term Investments of $9.9 million as of Q2 2022, which was down 49.16% from $19.4 million recorded in Q1 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' Short-term Investments peaked at $58.5 million during Q2 2018, and registered a low of $5.0 million during Q4 2019.
  • Moreover, its 3-year median value for Short-term Investments was $17.7 million (2021), whereas its average is $15.6 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Short-term Investments spiked by 120.44% in 2018 and then crashed by 86.44% in 2019.
  • Catalyst Pharmaceuticals' Short-term Investments (Quarterly) stood at $36.9 million in 2018, then slumped by 86.44% to $5.0 million in 2019, then surged by 100.54% to $10.0 million in 2020, then skyrocketed by 97.40% to $19.8 million in 2021, then slumped by 50.57% to $9.9 million in 2022.
  • Its last three reported values are $9.9 million in Q2 2022, $19.4 million for Q1 2022, and $19.8 million during Q4 2021.